DOI: https://dx.doi.org/10.18565/pharmateca.2021.7.138-145
T.Yu. Semiglazova (1, 2), Yu.V. Alekseeva (1), E.V. Tkachenko (1), S.M. Sharashenidze (1), I.A. Baldueva (1), S.A. Volchenkov (1), A.K. Kovyazin (1), L.V. Filatova (1, 2), B.S. Kasparov (1), V.V. Semiglazov (1, 3), S.A. Protsenko (1), V.N. Anisimov (1), A.M. Belyaev (1, 3)
1) N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; 2) North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; 3) Pavlov University, St. Petersburg, Russia
Corresponding author: Tatyana Yu. Semiglazova, Dr. Sci. (Med.), Associate Professor, Head of Department – Leading Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology; Professor at the Department of Oncology, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; tsemiglazova@mail.ru
Address: 68 Leningradskaya St., Pesochny settlement, St. Petersburg 197758, Russian Federation